|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Unité Inserm U524, Lille; Laboratoire
d'Hématologie A, CHRU, Lille; Laboratoire de
Cytogénétique, CHRU, Lille; Service des Maladies du Sang,
CHRU, Lille, France.
Targeting the tyrosine kinase activity of
BCR-ABL represents a very promising therapeutic
strategy in chronic myeloid leukemia (CML). Despite strong
efficacy of the tyrosine kinase inhibitor STI571, resistance has been
observed in a significant proportion of patients in advanced CML stage
or in Ph-positive acute lymphoid leukemia (ALL). We investigated in
this study the mechanism of resistance to STI571 through point
mutations in the tyrosine kinase domain and/or BCR-ABL gene
amplification in 24 patients (16 in chronic phase and 8 in accelerated
phase of the disease) who obtained no cytogenetic response to STI571
treatment. Screening for the already-described Thr315Ile point
mutation in the ABL domain using a reverse
transcription polymerase chain reaction restriction fragment
length polymorphism (RT-PCR-RFLP) technique, 3 patients showed
a proportion of mutated transcript at the time of resistance. The same
technique failed to detect mutation at diagnosis, but a specific
allele-specific oligonucleotide (ASO)-PCR on DNA for the Thr315Ile
mutation and, after sequencing, for 2 newly described Phe311Leu and
Met351Thr substitutions, showed the presence of rare mutated cells
prior to STI571 therapy. Furthermore, the increased proportion of
mutated cells during treatment detected by ASO-PCR strongly suggested
clonal selection by the functional inhibiting effect of these
mutations. Finally, no BCR-ABL gene amplification was detected by fluorescent in situ hybridization (FISH) in the 24 STI571-resistant patients. Our data support that in CML patients treated with STI571, ABL mutations are not restricted to
the accelerated phase of the disease and that, at least in some cases,
mutations seem to occur prior to STI571 therapy, probably as second
mutational events during the course of CML.
(Blood. 2002;100:1014-1018) Chronic myeloid leukemia (CML) is a hematopoietic
stem cell disorder characterized by the reciprocal chromosomal
translocation t(9;22)(q34;q11), resulting in a BCR-ABL
oncogenic fusion gene on Philadelphia (Ph) 22q-
chromosome.1-2 BCR-ABL encodes a cytoplasmic fusion protein with constitutive tyrosine kinase activity responsible for transformation and leukemogenic effects.3-4
CML progresses through distinct clinical stages: a chronic phase
characterized by expansion of terminally differentiated neutrophils; and an accelerated phase followed by blast crisis with undifferentiated myeloid or lymphoid progenitor cells in maturation arrest. Multiple additional genetic and molecular changes occur at this later disease stage.5
STI571 (Gleevec, Novartis) is a 2-phenylamino pyrimidine derivate that
competitively targets the adenosine 5'-triphosphate
(ATP)-binding site of the kinase domain of ABL with high
specificity6-8 and was recently approved by the Food and Drug Administration9 in the treatment of CML. STI571
induces hematological and cytogenetic remission in phase I and II
clinical trial patients in chronic phase as well as in blast
crisis10-11CML.
Primary refractoriness or relapse after initial response to STI571 is
observed in a significant proportion of patients in advanced CML stage
or in Ph-positive acute lymphoid leukemia11 and has been
associated with cell-intrinsic changes, including BCR-ABL
reactivation of the tyrosine kinase activity by gene
amplification12-14 and/or point mutations in the kinase
domain of BCR-ABL.9,15-16 Recently, Gorre et
al17 reported a Thr315Ile substitution induced by a C to T
base change in 9 of 29 acute-phase CML patients showing resistance to
STI571. In 2 European reports covering a total of 44 patients
also resistant to STI571, no Thr315Ile mutation was detected, but 2 mutations affecting Glu255 amino acid (1 Glu255Lys substitution and 1 Glu255Val substitution, induced by a G to A and A to T base changes,
respectively) were described.9,16 Crystallographic studies
showed that mutations affecting residues that are in direct contact
with ATP or are within the ATP pocket of the kinase domain could have
structural effects that influenced inhibition
sensitivity.18 The biologic significance of these amino
acid changes for STI571 tyrosine kinase inhibiting effect was confirmed
by autophosphorylation assays3 or by reconstitution experiments based on Crkl phosphorylation.15
We investigated the mechanism of resistance to STI571 in 24 CML
patients who obtained no cytogenetic response to STI571 therapy. Five
of them (2 in chronic and 3 in accelerated phase) had mutations in the
ABL tyrosine kinase domain at the time of resistance that were also demonstrated using sensitive allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) assays, prior to STI571 therapy. No
BCR-ABL gene amplification was detected by fluorescent in
situ hybridization (FISH) in our study.
Patients
Informed consent was obtained from all patients.
RT-PCR-RFLP assay
RNA extraction.
Total RNA was extracted from frozen aliquots of 107
peripheral blood leucocytes with Trizol reagent (Life Technologies,
United Kingdom) according to the manufacturer's instructions. RNA
pellets were resuspended in 10 µL RNAse-free water, and quantity was
estimated by ultraviolet spectrofluorometry.
Reverse transcription.
cDNA was synthesized from 1 µg total RNA in a 20 µL reaction
mixture as previously described.19
PCR amplification.
PCR amplification of a 412-base pair (bp) Abl fragment was
performed with 2 µL cDNA (corresponding to 100 ng total RNA); 1X TaqGold reaction buffer (Applied Biosystem, Foster City, CA); 1.5 mM MgCl2; 250 µM each dATP, dCTP, dGTP, and dTTP
(Pharmacia, Uppsala, Sweden); 0.5U AmpliTaq Gold polymerase
(Applied Biosystem); and 50 pmol primer F2: 5'GAG GGC GTG TGG
AAG AAA TA 3' and R2: 5' GCT GTG TAG GTG TCC CCT GT 3'. Thermocycling
conditions used were 12 minutes at 94°C followed by 35 cycles of
denaturation at 94°C for 1 minute, annealing at 57°C for 1 minute,
extension at 72°C for 1 minute, and a final extension step of 5 minutes at 72°C.
Restriction fragment length polymorphism (RFLP) analysis.
One fifth of PCR product was digested by 5U restriction enzyme
Dde I (Roche, Mannheim, Germany) and electrophoresed on
2.5% ethidium-bromide-stained agarose gel.
DNA extraction
Sequence analysis The whole kinase and ATP-loop ABL domain (amino acid 242 to 395) was amplified on cDNA in reaction mixture and PCR conditions as described above, using primer F3: 5'CAT CAC CAT GAA GCA CAA GC 3' and reverse primer R2 at 60°C for annealing.After purification on QIAquick PCR purification column (Qiagen), 462-bp PCR fragments were sequenced following the ABI protocol for Taq-Dye Terminator Sequencing on an automated ABI377 sequencer. Sequences were analyzed with the Sequence Analysis software V3.3 and the Sequence Navigator software V1.0.1 (Applied Biosystem). Sequencing was performed on both strands. Detected mutations were always confirmed by sequencing both strands of 207-bp PCR products from DNA. PCR conditions are described above, using forward primer F4: 5' GTC CTC GTT GTC TTG TTG GC 3' and reverse primer R4: 5' CCC CTA CCT GTG GAT GAA GT 3'at 60°C for annealing. ASO-PCR assays Mutated or wild-type sequences were specifically amplified in a noncompetitive PCR reaction performed on DNA in 50 µL reaction mixture and PCR conditions as described above, using allele-specific and reverse primers as follows: for the Thr315Ile mutation, F315C: 5' GCC CCC GTT CTA TAT CAT CAC 3' or F315T: 5' CCC GTT CTA TAT CAT CAT 3'and R1: 5' GGA TGA AGT TTT TCT TCT CCA G 3' (annealing at 64°C; 158-bp PCR product); for the Phe311Leu mutation, F311T: 5' CAC CCG GGA GCC CCC GT 3' or F311C: 5' CAC CCG GGA GCC CCC GC 3' and R4 (annealing at 64°C; 174-bp PCR fragment); for the Met351Thr mutation, F351T: 5'CCA CTC AGA TCT CGT CAG CCA T 3' or F351C: 5'CCA CTC AGA TCT CGT CAG CCA C 3' and R5: 5' GCC CTG AGA CCT CCT AGG CT 3' (annealing at 68 °C; 112-bp PCR fragment).The sensitivity of this assay was determined for each mutation by amplification of 10-fold limited dilutions of 100 ng patient's DNA at time of resistance in 100 ng healthy control DNA. FISH analysis Interphase nuclei were hybridized with fluorescent-labeled probes for BCR-ABL extra signal (ES) (Vysis, Downer Grove, IL) following standard procedure. For each slide, 500 nuclei were analyzed by 2 different observers.
Analysis of Thr315Ile mutation The recently described STI571-associated resistance mutation Thr315Ile was investigated by studying the loss of Dde I restriction enzyme site induced by C to T base change in our 24 STI571-resistant patients. Analysis was performed after cDNA amplification of a 412-bp PCR fragment at diagnosis and at the time of resistance.In 3 CML patients with resistance to STI571 (Figure
1; patients A, B, and C), the
Dde I-restricted pattern showed 2 populations of ABL
transcripts, a wild-type sequence characterized by 2 fragments of 171 and 36 bp, respectively, and a mutated sequence characterized by a
207-bp uncut fragment. Differences in band intensities
suggested a minor proportion of mutated transcript for patient A and a
major proportion of mutated transcript for patients B and C. This
RT-PCR-RFLP assay failed to detect Thr315Ile-mutated transcript at
diagnosis, as only a 207-bp uncut fragment was detected in
those patients.
Analysis was also performed on 16 patients with complete cytogenetic remission after 3 months of therapy with STI571. None of those patients presented the Thr315Ile mutation (data not shown). Direct sequence analysis on DNA and RNA In the 24 STI571-resistant patients, the ABL kinase domain and ATP-loop region were directly sequenced from PCR DNA and cDNA products (a 207-bp F4R4-PCR fragment and a 462-bp F3R2-PCR fragment, respectively) at the time of resistance and prior to STI therapy.Sequencing data confirmed the Thr315Ile mutation in 2 of the 3 previously RT-PCR-RFLP-detected patients, but failed in the remaining
patient (patient A, Figure 2), who
presented a lower level of mutated transcript (Figure 1). The
heterozygous rate for each patient is presented by comparison of
specific C and T signal ranges on chromatographic primary sequence
data, according to RT-PCR-RFLP pattern.
Two of the 21 remaining patients showed 2 previously unreported
mutations: one patient (patient D) in accelerated phase after 12 months
of STI571 therapy had a Phe311Leu substitution induced by a T to C base
change, and one patient (patient E) in chronic phase after 18 months of
STI571 therapy had a Met351Thr mutation induced by a T to C base change
(Figure 2). Clinical and biologic findings of the 5 mutated patients are summarized in Table
1.
No mutation affecting the Glu255 amino acid was detected by this direct sequencing method. ASO-PCR monitoring To increase the sensitivity of mutation detection, we developed ASO-PCR strategies. Figure 3 presents monitoring data and corresponding sensitivity for detected Thr315Ile, Phe311Leu, and Met351Thr mutations during STI571 therapy. Results show presence of the 3 mutated sequences on DNA in all patients at M0 prior to STI571 (data from patients A and B are not shown), providing evidence that those point mutations were pre-existent to STI571 treatment. An increased proportion of mutated cells over time is shown by PCR signal intensities on ethidium-bromide-stained agarose gel in the 3 analyzed mutations. This last result strongly suggests clonal selection by functional STI571 resistance of mutated cells during therapy. As specific PCR products of mutated ABL gene were detected even after a 10 000-fold dilution range, we developed a very sensitive ASO-PCR test: assuming that 100 ng DNA represent approximately 15 000 cells, we were able to detect 1.5 ABL-mutated cell in 15 000 wild-type cells. As expected, for each point dilution, signal intensity of nonmutated cells remained constant. The strong specificity of the assay was demonstrated for each mutation by lack detection of ABL sequence from healthy DNA controls.
FISH analysis BCR-ABL gene amplification has been described as a second STI571 mechanism of resistance.12-14 In our study, no BCR-ABL gene amplification was detected by FISH analysis at the time of resistance (data not shown).
No BCR-ABL gene amplification has been detected by FISH in any of the 24 CML patients resistant to STI571 studied here. On the other hand, using 3 different methodological approaches, we found the BCR-ABL Thr315Ile already-described gene mutation15 in 3 of the 24 CML patients, 2 in accelerated phase and one in chronic phase. This incidence of Thr315Ile mutation (ie, 3 of 24 patients, 12.5%) was somewhat lower than that reported by Gorre et al15,17 (ie, 6 of 25 patients, 24%) but higher than that reported in 2 previous European studies (0% of 44 patients). Direct sequencing failed to detect Thr315Ile mutation in one of our cases. Indeed, this technique can overlook mutations when the proportion of mutated cells is lower than 30% (as would probably be the case for patient A in our study; Figure 1). To maximize sensitivity, sequencing must be done on PCR products amplified with a BCR forward primer (to avoid coamplification of the normal ABL allele) or, better, on subcloned PCR products. This latter technical requirement possibly also explains why the Thr315Ile mutation was not found in 2 previous European reports.9,16 The lack of a Glu255 detected mutation in our study may also be explained by use of a low sensitivity procedure. Likewise, frequency of the 2 newly described ABL mutations in this report (Phe311Leu substitution in one patient in accelerated phase, and Met351Thr substitution in one patient in chronic phase) may have been underestimated as direct sequencing was performed. Taken together, our data and previous studies suggest that different mutations in the ABL kinase domain may be observed in CML patients resistant to STI571. Our study is also the first report of point mutations in the ABL gene in a chronic-phase CML patient, suggesting that this event is not restricted to patients in the blastic phase of the disease. Clonal evolution of mutated cells could be monitored over time by ASO-PCR. Our results revealed an increasing proportion of the 3 mutated Thr315Ile, Phe311Leu, and Met351Thr ABL sequences during STI571 therapy. Those results may support a functional effect of newly detected Phe311Leu and Met351Thr mutations on resistance to STI571, as already shown for Thr315Ile substitution.15 Because STI571 interacts with the kinase through hydrogen bonds, any mutation affecting amino acid residues in the active site of ABL could induce a structural effect, making the drug unable to inhibit ABL kinase activity. Nevertheless, further investigations on functional effect of 311 and 351 mutations would be necessary to confirm these points. Using this very sensitive ASO-PCR technique (sensitivity of 1/10 000), we also demonstrated the presence of rare cells bearing ABL mutations prior to STI571 therapy. This finding shows that, at least in the cases we studied, ABL mutations may be pre-existent to STI571, which only appears to create a clonal selection of the minor population of cells carrying the mutation. Origins of those point mutations of the ABL gene are uncertain, but mutations may have been acquired during disease progression through associated genetic instability. Of note is that none of our patients had been exposed to chemotherapy or radiotherapy. In conclusion, our study shows that among different mechanisms of resistance to STI571, BCR-ABL gene amplification is probably not the most frequent, but ABL mutations affecting binding of STI571 may be more prevalent. Our report seems to confirm that Thr315Ile substitution could be the most frequent mutation in CML.15,20 We report 2 other not previously described mutations, showing that several point mutations can be associated with STI571 resistance and that they are not restricted to the blastic phase of the disease. As we detected resistant mutated cells prior to therapy, at least some ABL mutations do not appear to be induced by STI571 but rather by secondary mutational events during the disease course pre-existent to STI571 treatment. Finally, we suggest the usefulness of detecting already-known STI571-resistant mutations in patient cells prior to therapy or at the early stage of treatment, using strategies such as ASO-PCR, in order to optimize therapeutic decision.
The authors are indebted to Dr Michel Crépin, Sabine Quief, and Institut Federatif de Recherche 22 for expert technical assistance. The authors also thank J. P. Kerckaert for critical reading of the manuscript.
Submitted November 29, 2001; accepted March 29, 2002.
Supported by the Comité Départemental du Nord de la Ligue Nationale contre le Cancer, by the Fondation de France contre le Cancer, by the Programme Hospitalier de Recherche Clinique 1997, and by the CHU de Lille.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Claude Preudhomme, Unité Inserm 524, 1 place de Verdun 59045 Lille Cedex, France; e-mail: cpreudhomme{at}chru-lille.fr.
1. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988;319:990-998[Medline] [Order article via Infotrieve].
2.
Melo JV.
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
Blood.
1996;88:2375-2384
3.
McLaughlin J, Chianese E, Witte ON.
In vitro transformation of immature hematopoietic cells by the p210 BCR-ABL oncogene product of the Philadelphia chromosome.
Proc Natl Acad Sci U S A.
1987;84:6558-6562
4.
Daley GQ, Van Etten RA, Baltimor D.
Induction of chronic myelogenous leukemia in mice by the p210 BCR-ABL gene of the Philadelphia chromosome.
Science.
1990;247:824-830
5.
Sawyers CL.
Chronic myeloid leukemia.
N Engl J Med.
1999;340:1330-1340 6. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med. 1996;2:561-566[CrossRef][Medline] [Order article via Infotrieve].
7.
Buchdunger E, Zimmerman J, Mett H, et al.
Inhibition of the Abl protein tyrosine kinase in vivo and in vitro by a 2-phenylaminopyrimidine derivative.
Cancer Res.
1996;56:100-104 8. Gambacoti-Passerini C, Le Coutre P, Mologni L, et al. Inhibition of the Abl kinase activity blocks the proliferation of BCR/ABL + leukemia cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380-394[CrossRef][Medline] [Order article via Infotrieve]. 9. Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI571 cancer therapy. Science. 2001;293:2163[CrossRef][Medline] [Order article via Infotrieve]
10.
Druker BJ, Talpaz M, Resta DJ, et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med.
2001;344:1031-1037
11.
Druker BJ, Sawyers CL, Kantarjian H, et al.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
N Engl J Med.
2001;344:1038-1042
12.
Le Coutre P, Tassi E, Varella-Garcia M, et al.
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.
Blood.
2000;95:1758-1766
13.
Weisberg E, Griffin JD.
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
Blood.
2000;95:3498-3505
14.
Mahon FX, Deininger M, Schultheis B, et al.
Selection and characterization of BCR-ABL-positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanism of resistance.
Blood.
2000;96:1070-1079
15.
Gorre EM, Mohammed M, Ellwood K, et al.
Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Science.
2001;293:876-880 16. Barthe C, Cony-Makhoul P, Melo JV, Mahon FX. Roots of clinical resistance to STI571 cancer therapy. Science. 2001;293:2163[CrossRef][Medline] [Order article via Infotrieve]. 17. Gorre EM, Shah N, Ellwood K, Nicoll J, Sawyers CL. Roots of clinical resistance to STI571 cancer therapy. Science. 2001;293:2163[CrossRef][Medline] [Order article via Infotrieve].
18.
Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J.
Structural mechanism for STI571 inhibition of Abelson tyrosine kinase.
Science.
2000;289:1938-1942
19.
Morschhauser F, Cayuela JM, Martini A, et al.
Evaluation of minimal residual disease using reverse transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.
J Clin Oncol.
2000;18:788-794 20. Bandford S, Rudzki Z, Walsh S, et al. Point mutations clustered within the ATP binding region of BCR-ABL are common in patients with emerging Glivec resistance but not in Glivec-responsive cases of CML [abstract]. Blood. 2001;98:3204.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  D. J. Kominsky, J. Klawitter, J. L. Brown, L. G. Boros, J. V. Melo, S. G. Eckhardt, and N. J. Serkova Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells Clin. Cancer Res., May 15, 2009; 15(10): 3442 - 3450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Khorashad, H. de Lavallade, J. F. Apperley, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al. Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression J. Clin. Oncol., October 10, 2008; 26(29): 4806 - 4813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Campbell, E. D. Pleasance, P. J. Stephens, E. Dicks, R. Rance, I. Goodhead, G. A. Follows, A. R. Green, P. A. Futreal, and M. R. Stratton Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing PNAS, September 2, 2008; 105(35): 13081 - 13086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ernst, J. Hoffmann, P. Erben, B. Hanfstein, A. Leitner, R. Hehlmann, A. Hochhaus, and M. C. Muller ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia Haematologica, September 1, 2008; 93(9): 1389 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Katsoulas, Z. Rachid, J. P. McNamee, C. Williams, and B. J. Jean-Claude Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia Mol. Cancer Ther., May 1, 2008; 7(5): 1033 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Roche-Lestienne, L. Deluche, S. Corm, I. Tigaud, S. Joha, N. Philippe, S. Geffroy, J.-L. Lai, F.-E. Nicolini, C. Preudhomme, et al. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance Blood, April 1, 2008; 111(7): 3735 - 3741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fojo Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better Oncologist, March 1, 2008; 13(3): 277 - 283. [Full Text] [PDF]
|
|
|
|
|
|
M. Copland, F. Pellicano, L. Richmond, E. K. Allan, A. Hamilton, F. Y. Lee, R. Weinmann, and T. L. Holyoake BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors Blood, March 1, 2008; 111(5): 2843 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods Blood, February 15, 2008; 111(4): 1774 - 1780. [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K.-K. Wong, M. Meyerson, and M. J. Eck The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP PNAS, February 12, 2008; 105(6): 2070 - 2075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF]
|
|
|
|
|
|
T. Ernst, P. Erben, M. C. Muller, P. Paschka, T. Schenk, J. Hoffmann, S. Kreil, P. La Rosee, R. Hehlmann, and A. Hochhaus Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib Haematologica, February 1, 2008; 93(2): 186 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Croce Oncogenes and Cancer N. Engl. J. Med., January 31, 2008; 358(5): 502 - 511. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Saglio, F. Pane, and G. Martinelli State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 313 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, C. A. Eide, and M. W. N. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood, October 1, 2007; 110(7): 2242 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Godin-Heymann, I. Bryant, M. N. Rivera, L. Ulkus, D. W. Bell, D. J. Riese II, J. Settleman, and D. A. Haber Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation Cancer Res., August 1, 2007; 67(15): 7319 - 7326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Pfeifer, B. Wassmann, A. Pavlova, L. Wunderle, J. Oldenburg, A. Binckebanck, T. Lange, A. Hochhaus, S. Wystub, P. Bruck, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood, July 15, 2007; 110(2): 727 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Modi, T. McDonald, S. Chu, J.-K. Yee, S. J. Forman, and R. Bhatia Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells Blood, June 15, 2007; 109(12): 5411 - 5421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Rodrigues and M. Sattler Chronic Myelogenous Leukemia Progenitors Display a Genetically Unstable Personality J Natl Cancer Inst, May 2, 2007; 99(9): 662 - 663. [Full Text] [PDF]
|
|
|
|
|
|
X. Jiang, K. M. Saw, A. Eaves, and C. Eaves Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells J Natl Cancer Inst, May 2, 2007; 99(9): 680 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Bartholomeusz, M. Talpaz, V. Kapuria, L. Y. Kong, S. Wang, Z. Estrov, W. Priebe, J. Wu, and N. J. Donato Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells Blood, April 15, 2007; 109(8): 3470 - 3478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Kantarjian, M. Talpaz, F. Giles, S. O'Brien, and J. Cortes New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance Ann Intern Med, December 19, 2006; 145(12): 913 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Skaggs, M. E. Gorre, A. Ryvkin, M. R. Burgess, Y. Xie, Y. Han, E. Komisopoulou, L. M. Brown, J. A. Loo, E. M. Landaw, et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants PNAS, December 19, 2006; 103(51): 19466 - 19471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Soverini, S. Colarossi, A. Gnani, G. Rosti, F. Castagnetti, A. Poerio, I. Iacobucci, M. Amabile, E. Abruzzese, E. Orlandi, et al. Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia Clin. Cancer Res., December 15, 2006; 12(24): 7374 - 7379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kosaka, Y. Yatabe, H. Endoh, K. Yoshida, T. Hida, M. Tsuboi, H. Tada, H. Kuwano, and T. Mitsudomi Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res., October 1, 2006; 12(19): 5764 - 5769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Bradeen, C. A. Eide, T. O'Hare, K. J. Johnson, S. G. Willis, F. Y. Lee, B. J. Druker, and M. W. Deininger Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations Blood, October 1, 2006; 108(7): 2332 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, September 15, 2006; 108(6): 1809 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Bubnoff, P. W. Manley, J. Mestan, J. Sanger, C. Peschel, and J. Duyster Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) Blood, August 15, 2006; 108(4): 1328 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Griswold, M. MacPartlin, T. Bumm, V. L. Goss, T. O'Hare, K. A. Lee, A. S. Corbin, E. P. Stoffregen, C. Smith, K. Johnson, et al. Kinase domain mutants of bcr-abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol. Cell. Biol., August 1, 2006; 26(16): 6082 - 6093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N. C. P. Cross, B. J. Druker, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood, July 1, 2006; 108(1): 28 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P. Shah, F. Y. Lee, R. Luo, Y. Jiang, M. Donker, and C. Akin Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis Blood, July 1, 2006; 108(1): 286 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Copland, A. Hamilton, L. J. Elrick, J. W. Baird, E. K. Allan, N. Jordanides, M. Barow, J. C. Mountford, and T. L. Holyoake Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction Blood, June 1, 2006; 107(11): 4532 - 4539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mishra, B. Zhang, J. M. Cunnick, N. Heisterkamp, and J. Groffen Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res., May 15, 2006; 66(10): 5387 - 5393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Z. Carter, D. H. Mak, W. D. Schober, M. Cabreira-Hansen, M. Beran, T. McQueen, W. Chen, and M. Andreeff Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells Blood, February 15, 2006; 107(4): 1555 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Barnes, D. Palaiologou, E. Panousopoulou, B. Schultheis, A. S.M. Yong, A. Wong, L. Pattacini, J. M. Goldman, and J. V. Melo Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Cancer Res., October 1, 2005; 65(19): 8912 - 8919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Willis, T. Lange, S. Demehri, S. Otto, L. Crossman, D. Niederwieser, E. P. Stoffregen, S. McWeeney, I. Kovacs, B. Park, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Blood, September 15, 2005; 106(6): 2128 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bianco, T. Troiani, G. Tortora, and F. Ciardiello Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S159 - S171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Soverini, G. Martinelli, G. Rosti, S. Bassi, M. Amabile, A. Poerio, B. Giannini, E. Trabacchi, F. Castagnetti, N. Testoni, et al. ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia J. Clin. Oncol., June 20, 2005; 23(18): 4100 - 4109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, D. K. Walters, E. P. Stoffregen, T. Jia, P. W. Manley, J. Mestan, S. W. Cowan-Jacob, F. Y. Lee, M. C. Heinrich, M. W.N. Deininger, et al. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants Cancer Res., June 1, 2005; 65(11): 4500 - 4505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Antonescu, P. Besmer, T. Guo, K. Arkun, G. Hom, B. Koryotowski, M. A. Leversha, P. D. Jeffrey, D. Desantis, S. Singer, et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation Clin. Cancer Res., June 1, 2005; 11(11): 4182 - 4190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Toyooka, K. Kiura, T. Mitsudomi, S. Kobayashi, D. G. Tenen, and B. Halmos EGFR Mutation and Response of Lung Cancer to Gefitinib N. Engl. J. Med., May 19, 2005; 352(20): 2136 - 2136. [Full Text] [PDF]
|
|
|
|
|
|
P.-H. Tseng, H.-P. Lin, J. Zhu, K.-F. Chen, E. M. Hade, D. C. Young, J. C. Byrd, M. Grever, K. Johnson, B. J. Druker, et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance Blood, May 15, 2005; 105(10): 4021 - 4027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bagrintseva, S. Geisenhof, R. Kern, S. Eichenlaub, C. Reindl, J. W. Ellwart, W. Hiddemann, and K. Spiekermann FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L) Blood, May 1, 2005; 105(9): 3679 - 3685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Deininger, E. Buchdunger, and B. J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood, April 1, 2005; 105(7): 2640 - 2653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Bubnoff, D. R. Veach, H. van der Kuip, W. E. Aulitzky, J. Sanger, P. Seipel, W. G. Bornmann, C. Peschel, B. Clarkson, and J. Duyster A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor Blood, February 15, 2005; 105(4): 1652 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Shah Loss of Response to Imatinib: Mechanisms and Management Hematology, January 1, 2005; 2005(1): 183 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies Blood, January 1, 2005; 105(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Branford, Z. Rudzki, I. Parkinson, A. Grigg, K. Taylor, J. F. Seymour, S. Durrant, P. Browett, A. P. Schwarer, C. Arthur, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations Blood, November 1, 2004; 104(9): 2926 - 2932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Corless, J. A. Fletcher, and M. C. Heinrich Biology of Gastrointestinal Stromal Tumors J. Clin. Oncol., September 15, 2004; 22(18): 3813 - 3825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Chen, J. C. Trent, E. F. Wu, G. N. Fuller, L. Ramdas, W. Zhang, A. K. Raymond, V. G. Prieto, C. O. Oyedeji, K. K. Hunt, et al. A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors Cancer Res., September 1, 2004; 64(17): 5913 - 5919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Shah, C. Tran, F. Y. Lee, P. Chen, D. Norris, and C. L. Sawyers Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor Science, July 16, 2004; 305(5682): 399 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A.E. Irving, S. O'Brien, A. L. Lennard, L. Minto, F. Lin, and A. G. Hall Use of Denaturing HPLC for Detection of Mutations in the BCR-ABL Kinase Domain in Patients Resistant to Imatinib Clin. Chem., July 1, 2004; 50(7): 1233 - 1237. [Full Text] [PDF]
|
|
|
|
|
|
S. Soverini, G. Martinelli, M. Amabile, A. Poerio, M. Bianchini, G. Rosti, F. Pane, G. Saglio, and M. Baccarani Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib Clin. Chem., July 1, 2004; 50(7): 1205 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-H. Liu, M. Kaur, G. Wang, P. Zhu, Y. Zhang, and G. M. Makrigiorgos Inverse PCR-Based RFLP Scanning Identifies Low-Level Mutation Signatures in Colon Cells and Tumors Cancer Res., April 1, 2004; 64(7): 2544 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gardembas, P. Rousselot, M. Tulliez, M. Vigier, A. Buzyn, F. Rigal-Huguet, L. Legros, M. Michallet, C. Berthou, N. Cheron, et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase Blood, December 15, 2003; 102(13): 4298 - 4305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Druker Imatinib As a Paradigm of Targeted Therapies J. Clin. Oncol., December 1, 2003; 21(90230): 239s - 245. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Goldman and J. V. Melo Chronic Myeloid Leukemia -- Advances in Biology and New Approaches to Treatment N. Engl. J. Med., October 9, 2003; 349(15): 1451 - 1464. [Full Text] [PDF]
|
|
|
|
|
|
N. von Bubnoff, D. R. Veach, W. T. Miller, W. Li, J. Sanger, C. Peschel, W. G. Bornmann, B. Clarkson, and J. Duyster Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine-Type Small Molecule Kinase Inhibitors Cancer Res., October 1, 2003; 63(19): 6395 - 6404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. N. Deininger and B. J. Druker Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib Pharmacol. Rev., September 1, 2003; 55(3): 401 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gambacorti-Passerini, R. Piazza, M. D'Incalci, A. Corbin, P. La Rosee, E. Stoffregen, B. Druker, and M. Deininger Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels Blood, September 1, 2003; 102(5): 1933 - 1935. [Full Text] [PDF]
|
|
|
|
|
|
W.-K. Hofmann, M. Komor, B. Wassmann, L. C. Jones, H. Gschaidmeier, D. Hoelzer, H. P. Koeffler, and O. G. Ottmann Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia Blood, July 15, 2003; 102(2): 659 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Branford, Z. Rudzki, S. Walsh, I. Parkinson, A. Grigg, J. Szer, K. Taylor, R. Herrmann, J. F. Seymour, C. Arthur, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood, July 1, 2003; 102(1): 276 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Zonder, P. Pemberton, H. Brandt, A. N. Mohamed, and C. A. Schiffer The Effect of Dose Increase of Imatinib Mesylate in Patients with Chronic or Accelerated Phase Chronic Myelogenous Leukemia with Inadequate Hematologic or Cytogenetic Response to Initial Treatment Clin. Cancer Res., June 1, 2003; 9(6): 2092 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Corbin, P. L. Rosee, E. P. Stoffregen, B. J. Druker, and M. W. Deininger Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib Blood, June 1, 2003; 101(11): 4611 - 4614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Roche-Lestienne, J.-L. Lai, S. Darre, T. Facon, and C. Preudhomme A Mutation Conferring Resistance to Imatinib at the Time of Diagnosis of Chronic Myelogenous Leukemia N. Engl. J. Med., May 29, 2003; 348(22): 2265 - 2266. [Full Text] [PDF]
|
|
|
|
|
|
J. V. Melo, T. P. Hughes, and J. F. Apperley Chronic Myeloid Leukemia Hematology, January 1, 2003; 2003(1): 132 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. La Rosee, A. S. Corbin, E. P. Stoffregen, M. W. Deininger, and B. J. Druker Activity of the Bcr-Abl Kinase Inhibitor PD180970 against Clinically Relevant Bcr-Abl Isoforms That Cause Resistance to Imatinib Mesylate (Gleevec, STI571) Cancer Res., December 15, 2002; 62(24): 7149 - 7153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich Chronic Myelogenous Leukemia Hematology, January 1, 2002; 2002(1): 111 - 135. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
were treated with STI571 in 3 multicenter
phase 2 trials (protocols nos. 110, 113, and 114) at our institution
between February 2000 and February 2001. After 3 months of therapy, 34 patients showed hematological and cytogenetic response to STI571 (ie,
normal blood counts and < 65% of Ph-positive mitoses), whereas 29 showed no cytogenetic response. Twenty-four of them, including 16 in
chronic phase and 8 in accelerated phase, were analyzed for
ABL gene mutation and amplification. No material was
available for the 5 remaining patients.
